BNP Paribas Financial Markets’s Drugs Made In America Acquisition II Corp DMII Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$3.94M Buy
394,950
+46,350
+13% +$462K ﹤0.01% 2201
2025
Q4
$3.45M Buy
+348,600
New +$3.45M ﹤0.01% 2279

Other funds holding DMII

BNP Paribas Financial Markets's DMII Position: Q1 2026 in Review

BNP Paribas Financial Markets increased its Drugs Made In America Acquisition II Corp (DMII) stake by 13% in Q1 2026, buying an estimated $462K and bringing the position to 394,950 shares worth $3.94M. The position accounts for ﹤0.01% of the portfolio, ranked #2201.

BNP Paribas Financial Markets first reported a position in DMII in Q4 2025 and has held it in 2 quarters since. 68 funds tracked by Wall St. Rank hold DMII as of Q1 2026.

  • BNP Paribas Financial Markets held 394,950 shares of Drugs Made In America Acquisition II Corp worth $3.94M as of Q1 2026.
  • BNP Paribas Financial Markets bought 46,350 Drugs Made In America Acquisition II Corp shares in Q1 2026, an estimated $462K.
  • Drugs Made In America Acquisition II Corp made up ﹤0.01% of BNP Paribas Financial Markets's portfolio in Q1 2026, its #2201 holding.
  • BNP Paribas Financial Markets first reported a position in Drugs Made In America Acquisition II Corp in Q4 2025 and has held it in 2 quarters since.
  • 68 funds tracked by Wall St. Rank held Drugs Made In America Acquisition II Corp as of Q1 2026.

Based on BNP Paribas Financial Markets's 13F filing for Q1 2026, filed 12 May 2026.